Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 7;28(10):2110–2117. doi: 10.1158/1078-0432.CCR-22-0041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 5. Kaplan–Meier plots of progression-free survival (PFS; A) and overall survival (OS; B) according to the expression of consensus molecular subtype (CMS). Patients with CMS1 showed significantly longer PFS [Not reached, NR (95% CI, NR–NR) vs. 4.8 months (95% CI, 1.1–30.7); P = 0.017] and numerically longer OS [Not reached (95% CI, NR–NR) vs. 31.0 months (95% CI, 2.6–NR); P = 0.105] than those with other types of CMS. — Kaplan–Meier plots of progression-free survival (PFS; A) and overall survival (OS; B) according to the expression of consensus molecular subtype (CMS). Patients with CMS1 showed significantly longer PFS [Not reached, NR (95% CI, NR–NR) vs. 4.8 months (95% CI, 1.1–30.7); P = 0.017] and numerically longer OS [Not reached (95% CI, NR–NR) vs. 31.0 months (95% CI, 2.6–NR); P = 0.105] than those with other types of CMS.